Efficacy and safety of switching psoriatic patients to bimekizumab : new evidence from clinical trials
| Errataetall: |
CommentOn: Br J Dermatol. 2023 Feb 22;188(3):330-340. - PMID 36751950 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
The British journal of dermatology - 188(2023), 3 vom: 22. Feb., Seite 316-317 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Valenti, Mario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
09495UIM6V |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 27.02.2023 published: Print CommentOn: Br J Dermatol. 2023 Feb 22;188(3):330-340. - PMID 36751950 Citation Status MEDLINE |
|---|
| doi: |
10.1093/bjd/ljac133 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352260246 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352260246 | ||
| 003 | DE-627 | ||
| 005 | 20231226053317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bjd/ljac133 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352260246 | ||
| 035 | |a (NLM)36715618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Valenti, Mario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of switching psoriatic patients to bimekizumab |b new evidence from clinical trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Br J Dermatol. 2023 Feb 22;188(3):330-340. - PMID 36751950 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a bimekizumab |2 NLM | |
| 650 | 7 | |a 09495UIM6V |2 NLM | |
| 650 | 7 | |a secukinumab |2 NLM | |
| 650 | 7 | |a DLG4EML025 |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 700 | 1 | |a Costanzo, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of dermatology |d 1951 |g 188(2023), 3 vom: 22. Feb., Seite 316-317 |w (DE-627)NLM000000361 |x 1365-2133 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2023 |g number:3 |g day:22 |g month:02 |g pages:316-317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/bjd/ljac133 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2023 |e 3 |b 22 |c 02 |h 316-317 | ||